Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.3252W HIGH $5.46
Volume
140.66 K
Value Traded
849.86 K
Short % Float
5.06%
Days to Cover
6.4
+6.48%Week
+12.64%1 Month
-8.5%3 Month
+1.96%6 Month
-33.25%5 Year
-84.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
108.46 M
EPS (TTM)
-0.30
P/E Ratio
-
Ent. Value
94.60 M
Total Shares
34.76 M
Float Shares
32.81 M
Insiders
5.62%
Institutions
15.47%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ANIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Anixa Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Anixa Biosciences, Inc.
417Total events
9Upcoming
54Tier-1 (high impact)
2013 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Additional Dataliraltagene autoleucelClinical Data
Four patients surpassed one year survival; fifth-cohort first patient stable disease at 90 days
recurrent ovarian cancersource ↗
▲Enrollment Completeliraltagene autoleucelTrial
Completion of dosing of fifth cohort in Phase 1 FSHR-targeted CAR-T trial
recurrent ovarian cancersource ↗
▲Safety Data Updateliraltagene autoleucelClinical Data
No dose-limiting toxicities observed across any cohort to date
recurrent ovarian cancersource ↗
▲Long Term Dataliraltagene autoleucelClinical Data
Multiple patients survived more than one year, one beyond two years
recurrent ovarian cancersource ↗
▲Additional Dataliraltagene autoleucelClinical Data
First case of stable disease for three months in ovarian cancer CAR-T trial
recurrent ovarian cancersource ↗
▲Safety Data Updateliraltagene autoleucelClinical Data
No dose-limiting toxicities observed to date
recurrent ovarian cancersource ↗
▲First Patient Dosedliraltagene autoleucelTrial
Second patient treated in fifth cohort of FSHR-targeted CAR-T Phase 1 trial
recurrent ovarian cancersource ↗
▲Safety Data Updateliraltagene autoleucelClinical Data
No dose-limiting toxicities observed across any cohort up to and including first patient in fifth cohort
recurrent ovarian cancersource ↗
▲Long Term Dataliraltagene autoleucelClinical Data
Four patients surpassed one year of survival; one beyond two years (approximately 28, 19, 17, 17 months)
recurrent ovarian cancersource ↗
▲Patent GrantedIP / Competition
IP Australia issues Patent Number 2020221280 for breast cancer vaccine technology
breast cancersource ↗
●Management ChangeCorporate
Carmen Guerra, M.D. appointed to Anixa Cancer Business Advisory Board
●R&D DayPresentation
Anixa breast cancer vaccine interview to air on RedChip Small Stocks, Big Money on Bloomberg TV
breast cancersource ↗
●Timing GuidancePresentation
Anixa breast cancer vaccine interview to air on RedChip show on Bloomberg TV
breast cancersource ↗
▲Primary Endpoint MetClinical Data
Breast cancer vaccine Phase 1 trial met all primary endpoints
breast cancersource ↗
◆Trial InitiationTrial
Preparations underway for Phase 2 trial of breast cancer vaccine
breast cancersource ↗
▲Enrollment Milestonelira-celFiledTrial
lira-cel advances to fifth and highest cohort with lymphodepletion
ovarian cancersource ↗
▲Dose Finding Updatelira-celFiledTrial
lira-cel advances to fifth and highest dose cohort with lymphodepletion
ovarian cancersource ↗
▲Safety Data Updatelira-celFiledClinical Data
No dose-limiting toxicities observed in lira-cel trial to date
ovarian cancersource ↗
▲Long Term Datalira-celFiledClinical Data
Four patients surpass one year survival, longest at approximately 28 months
ovarian cancersource ↗
▲Primary Endpoint MetClinical Data
Breast cancer vaccine final Phase 1 data shows all primary endpoints met
breast cancersource ↗
◆Trial InitiationTrial
Phase 2 trial preparations ongoing for breast cancer vaccine
breast cancersource ↗
▲Enrollment Milestonelira-celFiledTrial
lira-cel advanced to fifth and highest cohort with lymphodepletion
ovarian cancersource ↗
▲Patent GrantedIP / Competition
Australian patent accepted for breast cancer vaccine technology
breast cancersource ↗
▲Primary Endpoint MetClinical Data
Phase 1 breast cancer vaccine trial met all major primary endpoints, safe and well tolerated, immune responses in >74% of participants
breast cancersource ↗
▲First Patient Dosedlira-celFiledTrial
First patient treated in fifth cohort of Phase 1 FSHR-targeted CAR-T/CER-T trial
recurrent ovarian cancersource ↗
▲Enrollment Updatelira-celFiledTrial
Five patients surpassed one year survival; one beyond two years
recurrent ovarian cancersource ↗
▲Safety Data Updatelira-celFiledClinical Data
No dose-limiting toxicities observed across all cohorts up to 3x10^6/kg
recurrent ovarian cancersource ↗
▲Patent GrantedIP / Competition
Korean patent granted for breast cancer vaccine composition of matter
breast cancersource ↗
▲Primary Endpoint MetClinical Data
Phase 1 trial met all major primary endpoints, safe and well tolerated, immune responses in 74% of participants
breast cancersource ↗
▲Patent GrantedIP / Competition
Korean patent issued for breast cancer vaccine technology
breast cancersource ↗
▲Full ResultsClinical Data
Final Phase 1 data presented: all major primary endpoints met, immune responses in 74% of participants
breast cancersource ↗
◆Oral Presentationlira-celFiledPresentation
Presentation of ongoing Phase 1 trial of lira-cel highlighting survival observations
recurrent ovarian cancersource ↗
◆Poster Presentationlira-celFiledPresentation
Poster presentation of lira-cel Phase 1 trial design and current status at Frontiers in Cancer Immunotherapy symposium
recurrent ovarian cancersource ↗
◆Poster PresentationPresentation
Poster presentation of final Phase 1 data for breast cancer vaccine at Frontiers in Cancer Immunotherapy symposium
breast cancersource ↗
▲Primary Endpoint MetClinical Data
All major primary endpoints met in Phase 1 breast cancer vaccine trial
breast cancersource ↗
▲Patent GrantedIP / Competition
Canadian Notice of Allowance for ovarian cancer vaccine patent
ovarian cancersource ↗
▲Oral Presentationlira-celFiledPresentation
Presentation of updated survival data at ISCT 2026 Annual Meeting
recurrent ovarian cancersource ↗
▲Topline Readoutlira-celFiledClinical Data
Updated positive survival observations from ongoing Phase 1 trial
recurrent ovarian cancersource ↗
◆Oral Presentationlira-celFiledPresentation
Presentation at ISCT 2026 Annual Meeting
recurrent ovarian cancersource ↗
◆Oral PresentationPresentation
CEO interview airs on RedChip Small Stocks, Big Money show on Bloomberg TV
▲Primary Endpoint MetClinical Data
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in completed Phase 1 trial
breast cancersource ↗
▲Topline Readoutlira-celFiledClinical Data
Lira-cel exhibiting positive survival data in ongoing Phase 1 clinical trial
ovarian cancersource ↗
▲Patent GrantedIP / Competition
Mexican patent issued for breast cancer vaccine technology
breast cancersource ↗
◆Oral PresentationPresentation
Anixa to participate in Water Tower Research Insights Conference
◆Oral Presentationlira-celFiledPresentation
Presentation of lira-cel Phase 1 trial status at SGO Annual Meeting
recurrent ovarian cancersource ↗
▲Primary Endpoint MetClinical Data
Breast cancer vaccine met primary endpoints in Phase 1 trial
breast cancersource ↗
▲Topline Readoutlira-celFiledClinical Data
Lira-cel exhibiting positive survival data in ongoing Phase 1 trial
ovarian cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How ANIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-11 | Breast cancer vaccine | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 87%
Micro Cap(rank 572 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every ANIX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Titterton Lewis H jrDirector | Buy | 8,000 1,054,003 held | $2.98 | 10/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ANIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ANIX for Q2 2026. | ||||
ANIX Institutional Ownership Trends
ANIX Short Interest
Shares sold short, counted twice a month.
5.06%
Short % of Float
of tradable shares sold short
1.7M
Shares Sold Short
+23.1% vs prior count
6.4 High
Days to Cover
trading days of normal volume to buy every short share back
260.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ANIX ranks across every disease it competes in
Competitive Position is a premium feature
See how ANIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialANIX News
ANIXAnixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences completed dosing of the fifth cohort in its Phase 1 clinical trial for a CAR-T therapy targeting ovarian cancer. The trial reported that the first patient in this cohort exhibited stable disease 90 days after treatment. Notably, several patients have survived over one year, with one patient exceeding two years post-treatment. The study continues with plans for a sixth cohort after safety verification.
Read more →ANIX▼ -6%on this news
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference
Anixa Biosciences announced that Dr. Jose Conejo-Garcia will deliver a keynote at the 2026 Ovarian Cancer Midwest Focus Conference. His presentation will focus on overcoming ovarian cancer's resistance to immunotherapy. Anixa's CAR-T therapy, lira-cel, is currently in a Phase 1 trial and has shown encouraging results, including prolonged patient survival.
Read more →ANIXAnixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences announced a significant milestone in its Phase 1 clinical trial for a CAR-T therapy targeting ovarian cancer. The first patient in the fifth dose cohort showed stable disease for three months after treatment, with no dose-limiting toxicities reported. The trial aims to assess safety and preliminary efficacy of the therapy, which targets the follicle-stimulating hormone receptor.
Read more →ANIX▼ -5.5%on this newsshared move
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences has treated the second patient in the fifth cohort of its Phase 1 clinical trial for a CAR-T therapy targeting ovarian cancer. The trial has reported encouraging results, with several patients surviving over a year post-treatment and no dose-limiting toxicities observed. The study aims to evaluate the safety and efficacy of this novel therapy.
Read more →ANIXAnixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Anixa Biosciences has been granted a composition of matter patent for its breast cancer vaccine in Australia, valid through 2040. This patent strengthens the company's global intellectual property portfolio, which already includes protections in the U.S., Europe, China, and Japan. The vaccine has shown promising results in clinical trials, indicating potential for future development and commercialization.
Read more →ANIXAnixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences has appointed Dr. Carmen Guerra to its Cancer Business Advisory Board. Dr. Guerra, a prominent figure in cancer screening and clinical trials, will provide guidance as Anixa progresses its breast cancer vaccine into Phase 2 trials and continues its ovarian cancer CAR-T therapy in Phase 1. Her expertise is expected to significantly contribute to the company's mission in oncology.
Read more →ANIXAnixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences will feature an interview on Bloomberg TV discussing their breast cancer vaccine. Chairman and CEO Dr. Amit Kumar will highlight the vaccine's potential for treating and preventing breast cancer, while patient Sherie Steinberg will share her clinical trial experience. The segment aims to inform a broad audience about the advancements in cancer vaccine technology.
Read more →ANIXAnixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences will present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026. CEO Dr. Amit Kumar will discuss the company's clinical progress, including a CAR-T therapy for ovarian cancer and a breast cancer vaccine trial that met primary endpoints. The event aims to engage institutional investors.
Read more →ANIXAnixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences will present at the 2026 Cantor Fitzgerald Global Healthcare Conference, highlighting its advancements in a breast cancer vaccine and ovarian cancer CAR-T therapy. The breast cancer vaccine has met all primary endpoints in its Phase 1 trial, while the CAR-T therapy has shown promising survival rates in patients. The company is preparing for a Phase 2 trial for the vaccine and continues to evaluate the CAR-T therapy.
Read more →ANIXAnixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences will present at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting advancements in its ovarian cancer CAR-T therapy and breast cancer vaccine. The CAR-T therapy has reached the highest dose level with significant patient survival rates, while the breast cancer vaccine has met all primary endpoints in its Phase 1 trial. Preparations for a Phase 2 trial are underway.
Read more →ANIXAnixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences announced the acceptance of a new patent in Australia for its breast cancer vaccine technology, enhancing its global intellectual property coverage. The patent, licensed from Cleveland Clinic, supports Anixa's innovative approach to cancer prevention. Following positive results from a Phase 1 trial, the company aims to advance its clinical development and commercialization efforts internationally.
Read more →ANIX▼ -6.7%on this news
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences has treated the first patient in the fifth cohort of its Phase 1 clinical trial for a novel CAR-T therapy targeting ovarian cancer. This therapy has shown promising results, with five patients surviving over one year, including one patient beyond two years, and no dose-limiting toxicities reported. The trial aims to evaluate safety and preliminary efficacy in a challenging patient population.
Read more →ANIXAnixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences has been granted a composition of matter patent for its breast cancer vaccine in South Korea, valid through 2040. This patent expands Anixa's global intellectual property portfolio, which is crucial for pursuing regulatory approvals and partnerships. The vaccine has shown positive results in clinical trials, generating immune responses in 74% of participants.
Read more →ANIX▲ +6.5%on this news· ran to +20% by day 3shared move
Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences presented positive data from its breast cancer vaccine Phase 1 trial and ongoing CAR-T Phase 1 trial at the New York Academy of Sciences' symposium. The breast cancer vaccine met all primary endpoints, with 74% of participants showing immune responses. The CAR-T therapy, lira-cel, also reported encouraging survival observations. These developments underscore Anixa's progress in cancer immunotherapy.
Read more →ANIX▲ +5.5%on this news
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences announced the presentation of two clinical-stage immunotherapy programs at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy symposium. The presentations will cover their ovarian cancer CAR-T therapy, lira-cel, which shows positive survival data, and a breast cancer vaccine that met all primary endpoints in its Phase 1 trial. These presentations underscore Anixa's collaborations with leading cancer research institutions.
Read more →ANIXAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences has received a Notice of Allowance from the Canadian Intellectual Property Office for its ovarian cancer vaccine technology. This patent, licensed from Cleveland Clinic, aims to elicit an immune response targeting the AMHR2 protein. The technology is part of a broader strategy to develop cancer vaccines, complementing existing U.S. patent protections. Anixa's collaboration with Cleveland Clinic and NCI highlights its innovative approach to cancer prevention and treatment.
Read more →ANIXAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences has reported promising survival data from its ongoing Phase 1 trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer. Patients have shown substantial survival beyond the expected median, with one individual living for 28 months. The therapy is being evaluated for safety and efficacy, with no significant adverse effects noted thus far.
Read more →ANIXAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences will feature an interview with CEO Dr. Amit Kumar on Bloomberg TV, discussing the company's advancements in cancer treatment. The segment will highlight the positive results from a Phase 1 trial of their breast cancer vaccine and the encouraging survival data from their ovarian cancer CAR-T therapy. This interview aims to showcase Anixa's innovative approach and business model.
Read more →ANIXAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences has announced the issuance of a patent from the Mexican Institute of Industrial Property for its breast cancer vaccine technology, extending patent protection into 2040. This development is part of Anixa's strategy to expand its global patent portfolio, enabling potential partnerships for commercialization. The vaccine has shown positive Phase 1 clinical trial results, demonstrating safety and immune response in patients. Anixa aims to advance to a Phase 2 clinical trial based on these promising findings.
Read more →ANIX▲ +9%on this news
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences announced that Cheryl Cox will present at the ISCT 2026 Annual Meeting about the Phase 1 trial of lira-cel, a CAR-T therapy targeting ovarian cancer. The presentation will cover the trial's design and objectives, showcasing the ongoing positive survival data. The conference will gather global experts in cell and gene therapy.
Read more →About Anixa Biosciences, Inc.
Headquarters3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Founded1982
BIOPHARMAWATCH ELITE PLUS
Trade the next ANIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime